NTRK Fusion in Speicheldrüsentumoren — praktisch 100% der Säugetiere analoge Sekretor...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BMA-NTRK-FUSION-SALIVARY |
|---|---|
| Art | Therapeutische Relevanz |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Erkrankungen | DIS-SALIVARY |
| Quellen | SRC-FDA-CDS-2026 |
Fakten zur Handlungsfähigkeit
| Biomarker | BIO-NTRK-FUSION |
|---|---|
| Variante | NTRK1/2/3 Fusion (ETV6-NTRK3 definiert das säuerliche analoge Sekretkarzinom, MASC) |
| Erkrankung | DIS-SALIVARY |
| ESCAT-Stufe | IA |
| Empfohlene Kombinationen | larotrectinib monotherapy, entrectinib monotherapy (preferred for CNS disease) |
| Zusammenfassung der Beweise | NTRK fusion in salivary gland tumors — virtually 100% of mammary analogue secretory carcinoma (MASC) carry ETV6-NTRK3. Larotrectinib (NAVIGATE / pooled phase 1/2, Drilon NEJM 2018 — ORR 75% across tumor types, salivary subset ORR ~85%) and entrectinib (STARTRK-2 / ALKA / STARTRK-NG) are FDA-approved tumor-agnostic for NTRK-fusion solid tumors. Salivary MASC has among the highest response rates. |
Anmerkungen
ESCAT IA. OncoKB Level 1. MASC re-classified from acinic cell carcinoma in 2010 — driven entirely by ETV6-NTRK3 fusion. Detection: pan-TRK IHC screen → confirm by FISH or NGS. Resistance: solvent-front (NTRK G595R / G623R) and gatekeeper (G667C) mutations → next-gen TRK inhibitor selitrectinib / repotrectinib in trials. Source-gap: SRC-NCCN-HEAD-AND-NECK / SRC-NAVIGATE-DRILON-2018 / SRC-STARTRK2-DRILON-2020 not yet ingested.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.